NEWM&A

Sun Pharma (SUN) Acquires Organon for $11.75 Billion in Cash

Published on 4/27/2026

#SUN#M&A#pharmaceuticals#Organon#acquisition
Sun Pharma (SUN) Acquires Organon for $11.75 Billion in Cash

AI Summary

Sun Pharmaceutical Industries (SUN) announced its acquisition of Organon & Co for $11.75 billion, valuing the U.S. firm at $14 per share including debt. This deal will position Sun Pharma among the top 25 global pharmaceutical companies, enhancing its revenue from $12.4 billion. The acquisition is expected to increase Sun Pharma's innovative medicine segment contribution to 27% from 20% in the financial year ending March 2025. Organon's portfolio supports Sun Pharma's strategy to grow its Innovative Medicines business, which includes dermatology and oncology products.

Source: Read original article (opens in new tab)

Related News

Sun Pharma (SUN) Acquires Organon for $11.75 Billion
M&A

Sun Pharma (SUN) Acquires Organon for $11.75 Billion

Apr 27

Atlas Arteria (ALX) Receives $4.9B Takeover Bid from IFM Investors
M&A

Atlas Arteria (ALX) Receives $4.9B Takeover Bid from IFM Investors

Apr 26

Mayville Engineering (MEC) Shareholders Elect Board Until 2029
M&A

Mayville Engineering (MEC) Shareholders Elect Board Until 2029

Apr 26

Insulet Corporation (PODD) Faces Pressure from GLP-1 Threat
Markets

Insulet Corporation (PODD) Faces Pressure from GLP-1 Threat

Apr 26